300858 科拓生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.2175.3575.4518.25011.531
总资产报酬率 ROA (%)3.9535.0655.1917.76010.739
投入资产回报率 ROIC (%)4.1575.2685.3618.08511.344

边际利润分析
销售毛利率 (%)52.03858.25254.58251.97550.313
营业利润率 (%)33.10236.15134.28734.55834.201
息税前利润/营业总收入 (%)27.53227.85826.26233.17532.338
净利润/营业总收入 (%)28.51031.16231.23929.76730.042

收益指标分析
经营活动净收益/利润总额(%)90.38383.94387.84889.41177.507
价值变动净收益/利润总额(%)3.2275.1387.2377.43310.599
营业外收支净额/利润总额(%)-0.017-0.583-0.549-1.529-0.427

偿债能力分析
流动比率 (X)11.5779.92516.29615.56012.046
速动比率 (X)11.0049.44115.62714.96311.200
资产负债率 (%)5.9046.5794.2595.3087.046
带息债务/全部投入资本 (%)-0.384-0.0800.7370.9661.715
股东权益/带息债务 (%)-25,734.790-122,902.59313,323.43710,189.1205,668.954
股东权益/负债合计 (%)1,593.8311,419.9552,247.7411,783.7981,319.193
利息保障倍数 (X)-4.948-3.446-3.350-38.431-18.825

营运能力分析
应收账款周转天数 (天)61.45472.447101.453106.466115.992
存货周转天数 (天)99.880122.204119.403105.36796.953